The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027. The growth of the global rapid acting ...

TNDM Advancing Diabetes Technology With Ultra-Rapid Acting Insulin The t:slim X2 insulin pump, equipped with Control-IQ AID technology, is recognized for its ability to improve diabetes management ...

The initial therapeutic focus is diabetes, with three insulin-based products in development. Lead product is an ultra-rapid acting insulin, which the company hopes will outperform market rivals ...

In 1985, Novo Nordisk pioneered production of recombinant human insulin in yeast. In 1999, we introduced rapid-acting and, in 2004, long-acting insulin analogues produced by genetic engineering ...

Afrezza is a novel, ultra rapid-acting mealtime insulin therapy being developed for the control of hyperglycemia. The inhaled insulin device proved to be more effective than injected and oral ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

The present patient, who had diabetic nephropathy and retinopathy as secondary complications, was prescribed intensification therapy of subcutaneous injection of insulin (ultra-rapid-acting ...

THDB0206: Tonghua Dongbao Pharmaceutical BC Lispro (THDB0206) is an ultra-rapid-acting insulin analog developed by Tonghua Dongbao Pharmaceutical Co., Ltd. for the treatment of type 2 diabetes.